Higher-Cost Specialty Therapies Moving Up

Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawHigh-cost specialty therapies are no longer waiting their turn at the back of the treatment algorithm. Across multiple disease areas, drugs once reserved for later lines are moving steadily into first- and second-line use, according to several expert industry analysts.“When we looked at Crohn’s disease, we saw treatment shifting to newer options like IL-23 inhibitors and JAK [Janus kinase]inhibitor